US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

ADAP Adaptimmune Therapeutics PLC

0.58

-0.0069 (-1.18%)

Pre Mercado

Última actualización: 08:26:08

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

01/15/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Lunger John

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Adaptimmune Therapeutics (NASDAQ:ADAP)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025

Haga Click aquí para más Gráficas Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025

Haga Click aquí para más Gráficas Adaptimmune Therapeutics.

Noticias sobre Adaptimmune Therapeutics PLC ADAP

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 17 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 17 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Viernes 17 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Viernes 17 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 15 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 15 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 15 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Miércoles 15 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Miércoles 15 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Miércoles 15 de Enero 2025 (3 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Jueves 19 de Diciembre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Miércoles 13 de Noviembre 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Adaptimmune Therapeutics PLC Artículos de Noticias

SG Issuer Societe Generale

Aim Distribution Trust

PÃO DE AÇUCAR ON

Takeda Pharmaceutical

Absolute Health and Fitn... (CE)

Banco Bilbao Vizcaya Arg...

Invests Participacoes In... PN

Kinea Securities Fundo D...

Vontobel Financial Produ...

Societe Generale Effekten

Genesis Park Acquisition

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones